It’s been a crucial week for Atara Biotherapeutics, Inc. (NASDAQ:ATRA); here’s what analysts have to say.

May 18, 2018 - By Michael Taylor

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) LogoInvestors sentiment decreased to 1.42 in 2017 Q4. Its down 0.12, from 1.54 in 2017Q3. It is negative, as 9 investors sold Atara Biotherapeutics, Inc. shares while 17 reduced holdings. 12 funds opened positions while 25 raised stakes. 27.87 million shares or 6.54% more from 26.16 million shares in 2017Q3 were reported.
Moreover, Comml Bank Of Ny Mellon Corp has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Parallax Volatility Advisers L P holds 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 3,948 shares. Bank Of Montreal Can owns 4,591 shares or 0% of their US portfolio. Ameritas Invest holds 0% or 1,810 shares. Geode Cap Ltd Liability owns 196,841 shares. Great West Life Assurance Can invested 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Dekabank Deutsche Girozentrale, Germany-based fund reported 9,200 shares. 25,000 are owned by Pacific Heights Asset Ltd. Metropolitan Life Company Ny holds 9,283 shares. Pnc Svcs Gp Inc stated it has 34 shares. Harbourvest Llc invested in 0.15% or 10,543 shares. Tiaa Cref Investment Mgmt Limited Company holds 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 61,978 shares. Redmile Group Limited Com holds 2.22% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) or 2.82 million shares. Raymond James And Assocs invested in 25,325 shares or 0% of the stock. Deutsche Retail Bank Ag invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA).

Since December 12, 2017, it had 0 insider buys, and 27 insider sales for $17.62 million activity. Another trade for 4,647 shares valued at $214,026 was sold by Clark Mitchall G.. On Tuesday, May 15 Haqq Christopher sold $1.17 million worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) or 25,775 shares. The insider Gallagher Carol Giltner sold $12,574. The insider Porter Derrell sold $735,357. Fust Matthew K sold $535,301 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Monday, May 14. The insider MCGRATH JOHN sold 13,000 shares worth $611,925.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Ratings Coverage

Among 10 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 6 have Buy rating, 1 Sell and 3 Hold. Therefore 60% are positive. Atara Biotherapeutics had 11 analyst reports since December 29, 2017 according to SRatingsIntel. Canaccord Genuity maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Tuesday, January 30 with “Buy” rating. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Sell” rating given on Thursday, February 15 by Citigroup. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has “Neutral” rating given on Wednesday, January 3 by Citigroup. The stock has “Buy” rating by William Blair on Friday, April 6. J.P. Morgan initiated the stock with “Buy” rating in Tuesday, April 10 report. JMP Securities downgraded the shares of ATRA in report on Wednesday, February 28 to “Market Perform” rating. Jefferies maintained the stock with “Buy” rating in Monday, March 5 report. Below is a list of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) latest ratings and price target changes.

10/04/2018 Broker: JP Morgan Rating: Overweight New Target: $56 Initiates Coverage On
10/04/2018 Broker: J.P. Morgan Rating: Buy New Target: $56.0000 Initiate
06/04/2018 Broker: William Blair Rating: Buy Maintain
16/03/2018 Broker: Guggenheim Rating: Neutral Initiates Coverage On
05/03/2018 Broker: Jefferies Rating: Buy New Target: $46.0 Maintain
28/02/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Perform Downgrade
15/02/2018 Broker: Citigroup Old Rating: Neutral New Rating: Sell Downgrade
30/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $70.0 Maintain
26/01/2018 Broker: Cowen & Co Rating: Outperform Initiates Coverage On
03/01/2018 Broker: Citigroup Old Rating: Sell New Rating: Neutral Upgrade

The stock increased 1.27% or $0.6 during the last trading session, reaching $47.9. About 539,924 shares traded. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has risen 88.73% since May 18, 2017 and is uptrending. It has outperformed by 77.18% the S&P500.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $2.11 billion. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.

More notable recent Atara Biotherapeutics, Inc. (NASDAQ:ATRA) news were published by: which released: “Rounds Report: Omeros Rallied Robustly While Stellar FDA Due Diligence To Help Orphan Disease Innovators” on May 16, 2018, also with their article: “Atara Biotherapeutics: What Q1 2018 Earnings Foretell?” published on May 18, 2018, published: “Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)” on May 07, 2018. More interesting news about Atara Biotherapeutics, Inc. (NASDAQ:ATRA) were released by: and their article: “Atara Biotherapeutics Expands Commercial Leadership Team with the Appointment of Manuela Maronati as General …” published on May 01, 2018 as well as‘s news article titled: “Biotech Industry Veteran Dietmar Berger, MD, Ph.D., Joins Atara Biotherapeutics as Global Head of Research and …” with publication date: May 07, 2018.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: